Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKesson
Covington
Express Scripts
Deloitte
Cantor Fitzgerald
Medtronic
Queensland Health
Federal Trade Commission

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204026

« Back to Dashboard

NDA 204026 describes POMALYST, which is a drug marketed by Celgene and is included in one NDA. It is available from one supplier. There are fourteen patents protecting this drug and one Paragraph IV challenge. Additional details are available on the POMALYST profile page.

The generic ingredient in POMALYST is pomalidomide. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pomalidomide profile page.
Summary for 204026
Tradename:POMALYST
Applicant:Celgene
Ingredient:pomalidomide
Patents:14
Formulation / Manufacturing:see details
Pharmacology for NDA: 204026
Suppliers and Packaging for NDA: 204026
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
POMALYST pomalidomide CAPSULE;ORAL 204026 NDA Celgene Corporation 59572-501 N 59572-501-00
POMALYST pomalidomide CAPSULE;ORAL 204026 NDA Celgene Corporation 59572-501 N 59572-501-21

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength1MG
Approval Date:Feb 8, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Feb 8, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Apr 23, 2018
Regulatory Exclusivity Use:POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
Regulatory Exclusivity Expiration:Feb 8, 2020
Regulatory Exclusivity Use:TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.

Expired US Patents for NDA 204026

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-004 Feb 8, 2013 ➤ Sign Up ➤ Sign Up
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-001 Feb 8, 2013 ➤ Sign Up ➤ Sign Up
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-003 Feb 8, 2013 ➤ Sign Up ➤ Sign Up
Celgene POMALYST pomalidomide CAPSULE;ORAL 204026-002 Feb 8, 2013 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Moodys
Cipla
US Army
Boehringer Ingelheim
Queensland Health
Deloitte
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.